India Approves Two Coronavirus Vaccines for Emergency Use

Strategic Insights -

Indian authorities have approved two coronavirus vaccines for emergency use, granting permission to Serum and Bharat Biotech to manufacture the jabs. The approval comes as India, with a population of 1.3 billion, prepares to inoculate 300 million people on a priority list this year. The move is seen as a significant step towards containing the spread of the virus, which has recorded the second-highest number of infections worldwide. Meanwhile, some experts have raised concerns over the approval, citing the lack of Phase 3 trials for one of the vaccines.

Key Takeaways:

  • India's drug regulatory authority approved two coronavirus vaccines, Covishield and Covaxin, for restricted use in an emergency situation.
  • The vaccines were developed in collaboration with the Serum Institute of India, Bharat Biotech, and the Indian Council of Medical Research.
  • Covishield, developed by AstraZeneca and Oxford University, has shown an overall vaccine efficacy of 70.42% in clinical studies.
  • Covaxin, produced by Bharat Biotech, has demonstrated a robust immune response and has been found to be safe in Phase I and Phase II clinical trials.
  • The Indian government plans to inoculate 300 million people on a priority list this year, including healthcare workers, armed forces, and law enforcement personnel.
  • The approval has drawn praise from Prime Minister Narendra Modi, but has also faced criticism from some experts who have expressed concerns over the lack of Phase 3 trials for one of the vaccines.

Statistics:

  • 10.32 million: Total COVID-19 cases in India as of the latest available data.
  • 150,000: Total COVID-19 deaths in India as of the latest available data.
  • 18,000: New cases registered in India in the last 24 hours.
  • 217: Number of patients who died from COVID-19 in the last 24 hours.
  • 23,745: Number of participants in overseas clinical studies for Covishield.
  • 70.42%: Overall vaccine efficacy of Covishield in clinical studies.
  • 800: Number of participants in Phase I and Phase II clinical trials for Covaxin.
  • 25,800: Number of volunteers participating in the Phase III efficacy trial for Covaxin.
  • 22,500: Number of participants who have been vaccinated with Covaxin so far.
  • 1,600: Number of participants in Phase-II/III clinical trials for Covishield within the country.

Sources:

  • "Drugs Controller General of India grants emergency use authorization for vaccines" [1]
  • "India approves two vaccines for emergency use, Bharat Biotech's Covaxin raises eyebrows" [2]
  • "India to inoculate 300 million people on priority list this year" [3]
  • "Covishield vaccine efficacy: 70.42% in clinical studies" [4]
  • "Covaxin vaccine efficacy: robust immune response, safe in Phase I and Phase II clinical trials" [5]